Harvard Bioscience Inc. (HBIO) Financial Statements (2026 and earlier)

Company Profile

Business Address 84 OCTOBER HILL RD
HOLLISTON, MA 01746
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,1084,2834,5087,8218,3178,335
Cash and cash equivalent4,1084,2834,5087,8218,3178,335
Receivables14,86616,09916,70521,83417,76620,704
Inventory, net of allowances, customer advances and progress billings23,24524,71626,43927,58722,26222,061
Inventory23,24524,71626,43927,58722,26222,061
Other current assets2,8983,9403,4724,3413,3552,472
Total current assets:45,11749,03851,12461,58351,70053,572
Noncurrent Assets
Operating lease, right-of-use asset6,1324,7735,8166,8977,7618,463
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization5,1063,9813,3663,4153,9604,776
Intangible asset, including goodwill, after accumulated amortization67,45673,10177,27485,07491,74195,786
Goodwill56,32457,06556,26057,68958,59057,381
Intangible asset, excluding goodwill, after accumulated amortization11,13216,03621,01427,38533,15138,405
Other noncurrent assets2,8336,4737,7805,3751,0922,273
Total noncurrent assets:81,52788,32894,236100,761104,554111,298
TOTAL ASSETS:126,644137,366145,360162,344156,254164,870
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,7875,5546,4474,9115,9725,948
Taxes payable  609
Accounts payable4,7875,5546,4474,9115,9725,339
Deferred revenue3,8064,5083,3704,2663,7713,949
Debt  6,1394,0913,5152,0002,424
Other liabilities9,4099,2057,48610,7627,4786,091
Other undisclosed current liabilities 36,9561,1361,8551,8621,8326,900
Total current liabilities:54,95826,54223,24925,31621,05325,312
Noncurrent Liabilities
Long-term debt and lease obligation 30,70443,01351,58353,76755,141
Long-term debt, excluding current maturities 30,70443,01345,09546,28646,917
Liabilities, other than long-term debt8,3467,0466,8782,0444,7532,723
Deferred income tax liabilities7107765901,5581,8991,974
Other liabilities1,2551,4761,0064862,854749
Operating lease, liability6,3814,7945,2826,4887,4818,224
Total noncurrent liabilities:8,34637,75049,89153,62758,52057,864
Total liabilities:63,30464,29273,14078,94379,57383,176
Equity
Equity, attributable to parent, including:63,34073,07472,22083,40176,68181,694
Common stock441434454452444438
Additional paid in capital236,579232,435229,008225,650232,357229,189
Accumulated other comprehensive loss(15,670)(14,190)(15,052)(10,027)(13,066)(12,689)
Accumulated deficit(158,010)(145,605)(142,190)(132,674)(132,386)(124,576)
Other undisclosed equity, attributable to parent     (10,668)(10,668)
Total equity:63,34073,07472,22083,40176,68181,694
TOTAL LIABILITIES AND EQUITY:126,644137,366145,360162,344156,254164,870

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues94,135112,250113,335118,904102,100116,176
Cost of revenue
(Cost of Product and Service Sold)
(39,369)(46,179)(52,516)(51,252)(44,059)(51,854)
Gross profit:54,76666,07160,81967,65258,04164,322
Operating expenses(60,977)(64,177)(67,752)(65,586)(57,820)(63,945)
Operating income (loss):(6,211)1,894(6,933)2,066221377
Nonoperating expense(5,454)(4,450)(2,246)(2,206)(7,513)(5,879)
Other nonoperating income (expense)(652)(227)302(666)(806)(469)
Interest and debt expense    (393)(385)
Other undisclosed income from continuing operations before equity method investments, income taxes     393385
Loss from continuing operations before equity method investments, income taxes:(11,665)(2,556)(9,179)(140)(7,292)(5,502)
Other undisclosed income from continuing operations before income taxes      
Loss from continuing operations before income taxes:(11,665)(2,556)(9,179)(140)(7,292)(5,502)
Income tax expense (benefit)(740)(859)(337)(148)(518)815
Loss from continuing operations:(12,405)(3,415)(9,516)(288)(7,810)(4,687)
Loss before gain (loss) on sale of properties:(288)(7,810)(4,687)
Net loss available to common stockholders, diluted:(12,405)(3,415)(9,516)(288)(7,810)(4,687)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(12,405)(3,415)(9,516)(288)(7,810)(4,687)
Other comprehensive income (loss)(1,480)862(5,025)3,039(377)843
Comprehensive income (loss), net of tax, attributable to parent:(13,885)(2,553)(14,541)2,751(8,187)(3,844)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: